Abstract
INTRODUCTION
With the prevalence of obesity and metabolic sy ndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, including China [1] . Based on the "multiple hit" theory of NAFLD pathogenesis, lipid accumulation initiates simple hepatic steatosis and subsequently triggers multiple insults, ultimately inducing non alcoholic steatohepatitis (NASH), cirrhosis, and even hepatocellular carcinoma in predisposed individuals [2, 3] . Briefly, high levels of lipid metabolites, such as free fatty acids, could cause mitochondrial dysfunction, endoplasmic reticulum stress, and consequent ac tivation of inflammatory responses [4, 5] . In addition to the classical factors involved in the progression of NAFLD, epigenetic mechanisms are gradually identified as important regulators in the pathogenesis of this disease. The most thoroughly studied markers for epigenetic alterations in NALFD are DNA methylation and the actions of microRNAs [68] . MicroRNAs are noncoding RNAs composed of 18 to 25 nucleotides, and they play important roles in regulating a wide spectrum of biological processes, including fatty acid metabolism [9, 10] . Serum miR1925p levels have been reported to differentiate control livers, simple hepatic steatosis, and NASH in clinical studies [11] . Similarly, our previous research in NAFLD patients also found that serum miR1925p levels showed good correlations with hepatic steatosis and inflammatory activity [12] . Although miR1925p is abundant in the liver, early studies mainly focused on its regulatory role in cell growth, apoptosis, and tumor metastasis [13, 14] , little is known about its role in lipid metabolism.
StearoylCoA desaturase 1 (SCD1) plays an im portant role in the biosynthesis of monounsaturated fatty acids and serves as a key regulatory enzyme in the last stage of hepatic de novo lipogenesis (DNL). Increased DNL has been confirmed in NAFLD patients compared with controls [15] . Enhanced hepatic SCD1 activity promotes the accumulation of hepatic lipids, especially triglyceride (TG), and consequently leads to the progression of NAFLD [16] . Recent research has suggested that the expression of SCD1 may be re gulated through SREBP1cdependent and SREBP1c independent pathways [17] , but whether SCD1 can be regulated by microRNAs in NAFLD has not been fully studied.
To address the above questions, we conducted this study in highfat diet (HFD)fed rats and palmitic acid (PA)treated Huh7 cells. The hepatic and hepatocellular levels of miR1925p in NAFLD were evaluated both in vivo and in vitro. Overexpression and knockdown of miR1925p were performed in Huh7 cells to determine the regulatory effects of miR1925p in lipid accumulation, and luciferase reporter assays were used to confirm the direct interaction between miR192 5p and SCD1. Collectively, we attempted to illustrate the role of miR1925p in hepatic lipid metabolism in NAFLD.
MATERIALS AND METHODS

Animals and treatment
The animal experiment was designed to minimize pain or discomfort to the animals. A total of 30 male SpragueDawley rats (6wkold) were purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China) and were housed under controlled conditions of temperature (24 ℃ ± 2 ℃), humidity (50% ± 5%), and a light/dark cycle (12 h) with free access to food and water. After acclimation for one week on a standard diet, they were randomized into three groups (10 rats/group). The control group received a standard diet; the HFD group was fed an HFD (88% standard diet, 10% lard, and 2% cholesterol); and the therapy group was fed an HFD and received intraperitoneal injections of liraglutide (Sigma, St. Louis, United States; 0.6 mg/kg in saline solution) for the last 8 wk. This experiment followed the National Research Council's Guide for the Care and Use of Laboratory Animals and was approved by the Institutional Animal Care and Use Committee of SHRM (SHRMIACUC001).
Sample collection and measurement
At the end of 16 wk, the rats were euthanized after an overnight fast. Parts of the rat livers were fixed in 4% paraformaldehyde overnight and embedded in paraffin for histological assessments with hematoxylineosin (H&E) staining. The remaining portions were snap frozen in liquid nitrogen and stored at 80 ℃ for oil red O staining and other analyses. The hepatic TG levels of the rats were measured with an assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer's instructions.
Cell culture
The Huh7 cell line was obtained from American Type Culture Collection (ATCC; Manassas, VA, United States) and cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco, CA, United States) under an atmosphere of 5% CO2 at 37 ℃. PA powder (Sigma, St. Louis, United States) was dissolved in MilliQ water supplemented with 1% fatty acidfree BSA (Sigma, St. 
Cell viability detection
We performed cell viability measurements using the Cell Counting Kit8 (CCK8; Dojindo Molecular Technologies, Kumamoto, Japan) according to the manufacturer's instructions. Huh7 cells were plated onto a 96well plate and 0, 0.3, and 0.5 mmol/L of PA in culture medium was added for 8, 16 , and 24 h of incubation. The absorbance of the CCK8 was read at 450 nm, and the values were normalized to those of the control group.
Oil red O staining and intracellular TG assay
For oil red O staining, the cell culture plate was washed twice with phosphatebuffered saline and fixed in 10% neutral formalin. Oil red O (Sigma, St. Louis, United States) was dissolved in isopropanol as a stock solution and was diluted 3:2 with ddH2O to be added to the plate for 15 min, followed by washing in 60% isopropanol. Then, the plate was counterstained with hematoxylin after rinsing in distilled water. The intracellular TG levels in Huh7 cells were measured using a TG assay kit (Applygen Technologies Inc., Beijing, China) according to the manufacturer's instructions. Cellular TG levels were normalized to their protein contents. 
MiRNA and small interfering RNA (siRNA) transfection
Luciferase reporter assay
The sequence of the wild type (WT) or mutant (Mut) seed region of SCD1 was cloned into a psiCHECK2 luciferase vector (Promega, Madison, WI, United States) between XhoI and NotI sites. After being plated onto a 96well plate, 293T cells were transfected with 0.16 μg of a SCD1 3' untranslated region (UTR) vector (WT and Mut) and the empty vector as well as 50 nmol/L miR1925p mimic, 200 nmol/L inhibitor, and their respective NC. The culture medium was changed to complete DMEM after 6 h. Luciferase activity was measured using the Promega DualLuciferase system 48 h after transfection, and the relative luciferase activity was calculated as Renilla luciferase to Firefly luciferase.
Quantitative real-time polymerase chain reaction
Total RNA enriched with miRNA was isolated and extracted from frozen liver tissue and Huh7 cells chemiluminescent HRP substrate (Millipore Corporation, Billerica, MA, United States).
Statistical analysis
The data are expressed as the mean ± SEM. A statistical comparison was made using a twotailed Student ttest between two groups and a one way analysis of variance test followed by StudentNewman-Kuels analyses among multiple groups. Differences were considered significant at P < 0.05. All analyses were performed using GraphPad Prism 6.0 software (San Diego, CA, United States). The statistical methods used in this study were reviewed by Guang Yu Chen from Clinical Epidemiology Center, Shanghai Jiao Tong University.
RESULTS
miR-192-5p and SCD-1 levels in the liver of rat models
At the end of the 16 th week, all the rats in the HFD group developed NASH with significant hepatic macrovesicular steatosis, ballooning degeneration, and lobular inflammation. The mean body weight of the HFD rats (661.7 ± 15.8 g) was higher than that of the controls (566.7 ± 8.1 g, P < 0.01), and they also had increased hepatic TG levels (335 ± 9 mol/g) compared with the control group (101 ± 10 μmol/g, P < 0.01). The injection of liraglutide in HFD rats alleviated hepatic steatosis and reduced body weight (533.1 ± 7.4 g) and hepatic TG levels (241 ± 14 μmol/g) significantly (P < 0.01, Figure 1AC ). The analysis of serum biochemical parameters in animal models showed that the HFD rats had higher alanine transaminase (ALT), aspartate transaminase (AST), and low density lipoprotein (LDL) levels, and lower high density lipoprotein (HDL) levels compared with the control group (P < 0.05). The liraglutide group showed a significant decrease of ALT and AST compared with the HFD group (P < 0.05), but there was no statistical difference in serum LDL or HDL levels ( Table 1) . The qRTPCR results showed that HFD rats had decreased hepatic miR1925p levels (0.46fold) compared with the controls and that liraglutide therapy could abrogate the reduction of miR1925p in HFD rat livers (P < 0.01; Figure 1D ). In addition to decreased hepatic miR192 5p levels, the protein expression of hepatic SCD1 was markedly elevated (3.5fold) in rats fed an HFD, and liraglutide therapy could reduce hepatic SCD1 levels in HFD rats (P < 0.01; Figure 1E ).
Palmitate induces the down-regulation of miR-192-5p in vitro
According to the results of the CCK8 test, 0.5 mmol/L PA induced cell death as early as 8 h, but 0.3 mmol/L PA showed no significant cytotoxic effects until 16 h (Figure 2A 
Western blot analysis
Protein samples of 30 μg were analyzed by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The membranes were blocked with 5% skim milk in TBST for 2 h at room temperature and then incubated with mouse monoclonal antibody against SCD1 (Abcam, Cambridge, United Kingdom) and mouse monoclonal tubulin antibody (Beyotime, Shanghai, China) overnight at 4 ℃. Then, these membranes were washed and incubated at room temperature with an antimouse secondary antibody (Beyotime, Shanghai, China) for 1 h. Immune complexes were detected using a Western increased to approximately 45 μmol/g after exposure to 0.3 mmol/L PA for 8 h ( Figure 2B ), and the oil red O staining showed obvious lipid droplets in the cells ( Figure 2C ). Similar to HFD rat livers, the miR192 5p levels in PAtreated Huh7 cells showed significant downregulation (55%, P < 0.01) compared to the controls ( Figure 2D ). However, the SCD1 protein levels showed a 2.64fold increase in PAtreated Huh7 cells (P < 0.01; Figure 2E ).
SCD-1 is a direct target of miR-192-5p
Based on the results from the TargetScan, miRanda, and PicTar databases, there are hundreds of predicted targets for miR1925p. Among these, SCD1 is the one that participates in lipid metabolism and increase dramatically in NAFLD. Therefore, we performed dual luciferase reporter gene assays to validate the direct interaction between miR1925p and SCD1. The binding sites of miR1925p with 3' UTR of SCD1 are shown in Figure 3A , and the miR1925p seed sequence was deleted in mutant SCD1. The luciferase activity in WT SCD1 3' UTR was suppressed to 60% by miR1925p mimic and showed a 1.25fold increase by miR1925p inhibitor compared with their respective negative controls (P < 0.01). However, these re pressive and stimulatory effects could be abrogated by the mutation of the SCD1 3' UTR ( Figure 3B ), suggesting the direct interaction between miR192 5p and the 3' UTR of SCD1 mRNA. At the same time, we measured the mRNA levels of SCD1 in Huh7 cells when transfected with miR1925p mimic and inhibitor, but neither of them showed significant differences compared with their respective negative control ( Figure  3C ). Fortunately, we found an obvious reduction in SCD1 protein levels in Huh7 cells transfected with miR1925p mimic and an induction of these levels when transfected with miR1925p inhibitor compared with their separate negative control (P < 0.01; Figure  3D ).
miR-192-5p alleviates lipid accumulation by interacting with SCD-1
To evaluate the function of miR1925p in lipid metabolism, we transfected Huh7 cells with mimic NC and miR1925p mimic and cultured them in 0.3 mM PA medium. From oil red O staining, we found that the overexpression of miR1925p could alleviate lipid accumulation in Huh7 cells after exposure to PA for 8 hours ( Figure 4A ). As expected, Huh7 cells transfected with miR1925p mimic resulted in a significant reduction (23%) in cellular TG levels compared with mimic NC after PA exposure (P < 0.01; Figure 4B ). We further explored the regulatory effect of miR192 5p on SCD1 expression in PAtreated Huh7 cells. The protein levels of SCD1 were enriched significantly after PA exposure, and the increase could be blocked by the transfection of miR1925p mimic ( Figure 4C ).
SCD-1 mediates the promoting effect of the miR-192-5p inhibitor on lipid accumulation
To further investigate whether the regulation of lipid metabolism by miR1925p is mediated by SCD1, we applied SCD1 siRNA to perform the functional remedial experiment. As expected, the miR1925p inhibitor significantly increased the protein levels of SCD-1 in PAtreated Huh7 cells compared with its negative control, and the concomitant SCD1 siRNA transfection could abrogate the elevated SCD1 protein levels ( Figure  5A ). The inhibition of miR1925p could aggravate lipid accumulation in PAtreated Huh7 cells, but this could be reversed by SCD1 knockdown ( Figure 5B ). Similarly, cellular TG increased after the inhibition of miR1925p compared with its negative control, and this promoting effect could be blocked by the transfection of SCD1 siRNA (P < 0.01; Figure 5C ).
DISCUSSION
In the current study, we demonstrated that miR192 5p decreased in NAFLD both in vivo and in vitro and the decrease could be reversed after disease remission by liraglutide therapy in animal models. Meanwhile, we confirmed that miR-192-5p had a negative regulatory role in lipid synthesis, which was mediated through its regulation of lipogenetic gene SCD1. Because of the abundance of miR1925p in the liver, many researchers have focused on miR192 5p as a serum biomarker of liver injury. For example, serum levels of miR1925p have been found to increase in patients with various liver diseases, such as druginduced liver injury [18] , chronic hepatitis B [19] , hepatocellular carcinoma [20, 21] , and NAFLD [11, 22] . Serum miR122 and miR192 levels have been reported to differentiate control livers, simple hepatic steatosis, and NASH in clinical studies [11] . Similarly, our previous research in NAFLD patients also found that miR122, miR192, and miR34a showed good correlations with hepatic steatosis and inflammatory activity [12] . Among the three microRNAs, miR122 is the most studied in NAFLD and can regulate numerous genes involved in lipid metabolism, such as sterol regulatory element binding protein (SREBP), acetyl coenzyme A carboxylase 2 (ACC2), and 3hydroxy3methyl glutaryl coenzyme A reductase (HMGCR) [23, 24] .
Similarly, miR34a is characterized as a regulator of peroxisome proliferatoractivated receptor α (PPARα) and its downstream genes and it induces lipid accumulation in a hepatocyte nuclear factor 4α (HNF 4α)dependent way [25, 26] . However, the regulatory role of miR1925p in NAFLD remains unknown. In our in vivo and in vitro models of NAFLD, miR192 5p decreased in livers with steatosis and in cells with lipid accumulation. Because liraglutide is a wellknown therapeutic option for weight loss and NAFLD [27] , the injection of liraglutide in HFD rats significantly alleviated the steatosis and hepatic TG levels, accompanied by the induction of hepatic miR1925p levels. These results may indicate that miR1925p has a negative correlation with hepatic lipid accumulation.
Originally, miR1925p was identified as an oncogene in some cancers and shows a negative correlation with the liver metastatic potential of colon cancer cells [28] . The expression of miR1925p is regulated partly by transforming growth factor β1 (TGFβ1) and hepatocyte nuclear factor 4α (HNF4α) [29, 30] . A study by Roy et al shows that hepatic miR1925p can protect against acute liver injury induced by oxidative stress through the mediation of target gene Zeb2, which is a principal transcriptional regulator in cell survival [13] . Furthermore, docosahexaenoic acid can upregulate miR192 levels in enterocytelike Caco2 cells, and miR192 shows a repressive effect on the expression of genes involved in lipid metabolism, such as insulin like growth factor 1 (IGF1), fatty acid binding protein 3 (FABP3), and very lowdensity lipoprotein receptor (VLDLR) [31] . Recently, miR1925p was reported to play a role in bisphenol Atriggered NAFLD by regulating SREBF1 [32] . In our NASH animal models fed an HFD and in the Huh7 cells treated with saturated fatty acid PA, which are the most recognized models for this disease, we demonstrated that the hepatic and cellular levels of miR-192-5p decreased significantly and that the overexpression of miR1925p could alleviate lipid accumulation in Huh7 cells. These results suggested that, in addition to its role in cell death and apoptosis, miR1925p could participate in lipid metabolism in NAFLD.
In the livers of NAFLD patients, fat accumulates because of an imbalance between lipid deposition and removal, which is driven by the hepatic synthesis of TG and DNL, especially in conditions of insulin resistance [16, 33] . The contribution of DNL to hepatic TG synthesis and oxidative stress is significant, so inhibitors of DNL, such as Aramchol, are important NAFLD treatments for reducing hepatic fat accumulation [34, 35] . SREBP1c is reported to be the predominant regulator of DNL in the liver and activates key lipogenic genes such as SCD1 [17] . Meanwhile, hepatic SCD1 can also induce hepatic steatosis independent of upstream regulation by SREBP1c [36] . SCD1 is an enzyme that catalyzes the desaturation of fatty acylCoA substrates and participates in the biosynthesis of monounsaturated fatty acids, which constitute the primary components of TG [37] . Increased SCD1 activity accelerates the last stage of TG synthesis and stimulates lipid accumulation [38] , but repressed SCD1 expression upregulates the components in the insulin signaling pathway [39] and reduces obesity in HFD fed animal models [40] . Our present study showed an increase in hepatic SCD1 levels in rats fed an HFD, and treatment with liraglutide could decrease its levels dramatically.
In addition to regulation by upstream transcription factors, SCD1 may be repressed through a mi Recent studies have demonstrated the roles of miR125b and miR29a in the regulation of SCD1 [41, 42] . In our study, we found that a region of the SCD 3' UTR completely matched a seed sequence (5'UGACCUA3') at the binding site of miR1925p, demonstrating a direct interaction between miR1925p and SCD1. The knockdown and overexpression of miR1925p in Huh7 cells showed significant promotion and inhibition effects, respectively, on the protein expression of SCD1, but no effects were observed on the mRNA levels of this gene. This result suggested that miR 1925p could regulate the SCD1 expression at the posttranscriptional level. Since the mRNA targets are only partially complementary to microRNAs in animals, microRNAinduced silencing complexes can mediate posttranscriptional silencing in the absence of mRNA degradation [43] . In addition, the functional remedial experiment showed that the transfection with SCD1 siRNA could significantly abrogate the lipid accumulation induced by miR1925p inhibitor, indicating that miR1925p regulated lipid metabolism at least partly through an interaction with SCD1.
The potential limitation of our study is that the specific regulatory role of miR1925p in NAFLD has not been thoroughly validated in vivo. Although one study demonstrated that the overexpression of miR 1925p could abrogate bisphenol Ainduced hepatic steatosis and lipid accumulation in C57BL/6 mice, whether miR1925p can alleviate hepatic steatosis in NAFLD patients remains uncertain. Therefore, hepatic miR1925p levels and the treatment effect of miR 1925p need to be validated in clinical practice. It may be difficult to acquire enough participants due to the invasive method required for the retrieval of liver samples from NAFLD patients, but it would be of practical implications if clinical experiments support our claims going forward. In addition, as the therapy with liraglutide in NAFLD is accompanied by the upregulation of hepatic miR1925p levels, the rationale between liraglutide and hepatic miR1925p is also an open question.
In conclusion, we demonstrated that hepatic miR 1925p levels decreased in NASH rat models fed an HFD and that this decrease could be reversed after disease remission by liraglutide therapy. We first confirmed that miR1925p had a direct regulatory effect on lipogenetic gene SCD1 and that this mediated the negative regulatory effect of miR192 5p in lipid synthesis in NAFLD. These data complement the regulators involved in the progression of NAFLD and help us better understand the role of epigenetic factors in this disease. Meanwhile, our study suggests that the overexpression of miR-192-5p may reflect a promising treatment strategy for NAFLD, which calls for more validated data in the future.
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Research background
Based on the "multiple hit" theory of non-alcoholic fatty liver disease (NAFLD) pathogenesis, lipid accumulation initiates simple hepatic steatosis and subsequently triggers multiple insults, ultimately inducing non-alcoholic steatohepatitis, cirrhosis, and even hepatocellular carcinoma. In addition to the classical factors involved in the progression of NAFLD, microRNAs, which represent epigenetic alterations, have been identified as important posttranscriptional regulators in the pathogenesis of this disease.
Research motivation
Due to the abundance of miR-192-5p in the liver, many researchers have focused on miR-192-5p as a serum biomarker of liver injury, such as druginduced liver injury, chronic hepatitis B, hepatocellular carcinoma, and NAFLD. Because microRNAs are important regulators in a wide spectrum of biological processes and metabolic homeostasis, the role of microRNAs in NAFLD pathogenesis is of particular interest. Our previous research in NAFLD patients found that serum miR-192-5p levels could differentiate different stages of NAFLD and showed good correlations with hepatic steatosis and inflammatory activity, but little is known about its regulatory role in lipid metabolism.
Research objectives
We aimed to evaluate the hepatic levels of miR-192-5p in rat models of NAFLD, and figure out the role of miR-192-5p in lipid metabolism. After the present study, we have identified the lipogenetic gene SCD-1 as a target gene of miR-192-5p, confirming the negative regulatory effect of miR-192-5p in lipid synthesis in NAFLD. These realized objectives give us a better understanding about the functional mechanism of miR-192-5p in NALFD and provide a new insight in the miRNA-intervention treatment strategy for this disease.
Research methods
We conducted this study in HFD-fed rats and palmitic acid-treated Huh7 cells. The hepatic and hepatocellular levels of miR-192-5p in NAFLD were evaluated using quantitative real-time polymerase chain reaction both in vivo and in vitro. The SCD-1 protein levels were examined by Western blot analysis. Oil red O staining and TG assay were used to detect the lipid accumulation in rat livers and hepatocytes. Overexpression and knockdown of miR-192-5p were performed in Huh7 cells with miR-192-5p mimic and inhibitor. Luciferase reporter assays confirmed the direct interaction between miR-192-5p and SCD-1.
Research results
In the current study, we found that miR-192-5p decreased in NAFLD both in vivo and in vitro and the decrease could be reversed after disease remission by liraglutide therapy in animal models. Meanwhile, we confirmed that miR-192-5p had a negative regulatory role in lipid synthesis, which was mediated through its regulation on lipogenetic gene SCD-1. However, the specific regulatory role of miR-192-5p in NAFLD patients remains unclear, which needs to be validated in clinical studies.
Research conclusions
The authors demonstrated that miR-192-5p decreased in NAFLD conditions both in vivo and in vitro, which could provide more evidence for the clinical use of circulating miR-192-5p as a biomarker in NAFLD. We first confirmed that miR-192-5p showed direct regulation on lipogenetic gene SCD-1 and that this could mediate the negative regulatory effect of miR-192-5p in lipid synthesis in NAFLD. These data complement the regulators involved in the progression of NAFLD and help us better understand the role of epigenetic factors in this ARTICLE HIGHLIGHTS disease. Meanwhile, the study suggests that the overexpression of miR-192-5p may reflect a promising treatment strategy for NAFLD, which calls for more validated data in the future.
Research perspectives
This study suggests that the miRNA intervention may be a promising treatment strategy for NAFLD. The future study might focus on the specific regulatory role of miR-192-5p in NAFLD in vivo, and the therapeutic effect of miR-192-5p needs to be validated in clinical practice. It would be of practical implications if clinical experiments support our claims going forward.
